alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 32****Certifications Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)**     The undersigned, as the President and Chief Executive Officer, and Executive Vice Presidentand Chief Financial Officer of Exide Technologies, each certify that     (1) the accompanying Quarterly Report on Form 10-Q for the period ended June 30, 2007, fullycomplies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities ExchangeAct of 1934, as amended; and     (2) the information contained in the periodic report fairly presents, in all materialrespects, the financial condition and results of operations of Exide Technologies at the dates andfor the periods indicated.     A signed original of this written statement required by Section 906 has been provided to ExideTechnologies and will be retained by Exide Technologies and furnished to the Securities andExchange Commission or its staff upon request.     The undersigned expressly disclaims any obligation to update the foregoing certificationexcept as required by law.Date: August 7, 2007       /S/ Gordon A. Ulsh              Gordon A. Ulsh    President and Chief Executive Officer         /S/ Francis M. Corby, Jr.              Francis M. Corby, Jr.    Executive Vice President and    Chief Financial Officer  
33
§ 352.3 Definitions. As used in this part: ( a ) *Minimal erythema dose (MED).* The quantity of erythema-effective energy (expressed as Joules per square meter) required to produce the first perceptible, redness reaction with clearly defined borders.
( b ) *Product category designation (PCD).* A labeling designation for sunscreen drug products to aid in selecting the type of product best suited to an individual's complexion (pigmentation) and desired response to ultraviolet (UV) radiation. ( 1 ) *Minimal sun protection product.* A sunscreen product that provides a sun protection factor (SPF) value of 2 to under 12.
( 2 ) *Moderate sun protection product.* A sunscreen product that provides an SPF value of 12 to under 30.
( 3 ) *High sun protection product.* A sunscreen product that provides an SPF value of 30 or above.
( c ) *Sunscreen active ingredient.* An active ingredient listed in § 352.10 that absorbs, reflects, or scatters radiation in the UV range at wavelengths from 290 to 400 nanometers.
( d ) *Sun protection factor (SPF) value.* The UV energy required to produce an MED on protected skin divided by the UV energy required to produce an MED on unprotected skin, which may also be defined by the following ratio: SPF value = MED (protected skin (PS))/MED (unprotected skin (US)), where MED (PS) is the minimal erythema dose for protected skin after application of 2 milligrams per square centimeter of the final formulation of the sunscreen product, and MED (US) is the minimal erythema dose for unprotected skin, *i.e.*, skin to which no sunscreen product has been applied. In effect, the SPF value is the reciprocal of the effective transmission of the product viewed as a UV radiation filter.
§ 520.88c Amoxicillin trihydrate oral suspension. ( a ) *Specifications.* Each 0.8-milliliter dose contains amoxicillin trihydrate equivalent to 40 milligrams (mg) amoxicillin.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.38 of this chapter.
( d ) *Conditions of use in swine* — ( 1 ) *Amount.* Administer 40 mg orally twice a day using a dosing pump. Treat animals for 48 hours after all symptoms have subsided but not beyond 5 days.
( 2 ) *Indications for use.* Treatment of baby pigs under 10 pounds for porcine colibacillosis caused by *Escherichia coli* susceptible to amoxicillin.
( 3 ) *Limitations.* Do not slaughter during treatment or for 15 days after latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37319, Aug. 18, 1992, as amended at 60 FR 55658, Nov. 2, 1995; 79 FR 28817, May 20, 2014; 85 FR 18118, Apr. 1, 2020]
§ 182.640 Employee. ( a ) Employee means the employee of a recipient directly engaged in the performance of work under the award, including— ( 1 ) All direct charge employees;
( 2 ) All indirect charge employees, unless their impact or involvement in the performance of work under the award is insignificant to the performance of the award; and
( 3 ) Temporary personnel and consultants who are directly engaged in the performance of work under the award and who are on the recipient's payroll.
( b ) This definition does not include workers not on the payroll of the recipient (e.g., volunteers, even if used to meet a matching requirement; consultants or independent contractors not on the payroll; or employees of subrecipients or subcontractors in covered workplaces).
<PAGE>   1
                                                                    EXHIBIT 24.1


                                POWER OF ATTORNEY


         Know by all these presents, that the undersigned hereby constitutes and
appoints Gordon A. Gardiner and Larry W. Martin, or either of them, the
undersigned's true and lawful attorney-in-fact to:

         (1)      execute for and on behalf of the undersigned, in the
                  undersigned's capacity as a director of Data Dimensions, Inc.
                  (the "Company"), a registration statement on Form S-8,
                  registering 157,625 shares of the Company's Common Stock
                  issuable upon exercise of options granted pursuant to the ST
                  Labs 1995 and 1997 Stock Option Plans.

         (2)      do and perform any and all acts or and on behalf of the
                  undersigned which may be necessary or desirable to complete
                  and execute any such registration statement on Form S-8 and
                  timely file such registration statement with the United States
                  Securities and Exchange Commission and any stock exchange or
                  similar authority; and

         (3)      take any other action of any type whatsoever in connection
                  with the foregoing which, in the opinion of such
                  attorney-in-fact, may be of benefit to, in the best interest
                  of, or legally required by, the undersigned, it being
                  understood that the documents executed by such
                  attorney-in-fact on behalf of the undersigned pursuant to this
                  Power of Attorney shall be in such form and shall contain such
                  terms and conditions as such attorney-in-fact may approve in
                  such attorney-in-fact's discretion.

         The undersigned hereby grants to such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this Power of Attorney and the rights and powers herein
granted.

         This Power of Attorney shall remain in full force and effect until
revoked by the undersigned in a signed writing delivered to the foregoing
attorney-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this _____ day of ___________________, 1998.

                                             /s/ THOMAS W. FIFE
                                             -----------------------------------
                                             Thomas W. Fife
[Federal Register Volume 75, Number 6 (Monday, January 11, 2010)]
[Notices]
[Page 1425]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-391]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION


Sunshine Act Meeting Notice

    Notice is hereby given, pursuant to the provisions of the 
Government in the Sunshine Act, Public Law 94-409, that the Securities 
and Exchange Commission will hold a Closed Meeting on Thursday, January 
14, 2010 at 2 p.m.
    Commissioners, Counsel to the Commissioners, the Secretary to the 
Commission, and recording secretaries will attend the Closed Meeting. 
Certain staff members who have an interest in the matters also may be 
present.
    The General Counsel of the Commission, or his designee, has 
certified that, in his opinion, one or more of the exemptions set forth 
in 5 U.S.C. 552b(c)(3), (5), (7), 9(B) and (10) and 17 CFR 
200.402(a)(3), (5), (7), 9(ii) and (10), permit consideration of the 
scheduled matters at the Closed Meeting.
    Commissioner Paredes, as duty officer, voted to consider the items 
listed for the Closed Meeting in a closed session.
    The subject matter of the Closed Meeting scheduled for Thursday, 
January 14, 2010 will be:

[I]nstitution and settlement of injunctive actions; institution and 
settlement of administrative proceedings; consideration of amicus 
participation; and
Other matters relating to enforcement proceedings.

    At times, changes in Commission priorities require alterations in 
the scheduling of meeting items.
    For further information and to ascertain what, if any, matters have 
been added, deleted or postponed, please contact:
    The Office of the Secretary at (202) 551-5400.

    Dated: January 7, 2010.
Elizabeth M. Murphy,
Secretary.
[FR Doc. 2010-391 Filed 1-7-10; 4:15 pm]
BILLING CODE 8011-01-P
DHS – HSIN Advisory Committee (AC) MEETING

1300 Pennsylvania Avenue NW Washington, D.C. 20004

February 27th- 28th

Open to the Public and Press

1

HSIN Advisory Committee Agenda

February 27-28, 2013

(Day ONE: February 27, 2013)

TIME SESSION SPEAKER

9:00 – 9:15 a.m. Welcome, Admin/Housekeeping Issues David Steigman

9:15 – 9:35 a.m. HSIN Today: HSIN in the Real World Katie Mullins

9:35 – 10:00 a.m. How Far We’ve Come Since 2010: Jim Lanoue

10:00 – 10:30 a.m. HSIN R3 Value Proposition & New 

Features

Donna Roy

10:30 – 10:45 a.m. Break

10:45 – 11:05 a.m. How We’ve Acted on Your 

Recommendations Since 2010

Donna Roy

11:05 – 11:30 a.m. HSIN Release 3 Requirements and 

Development

Tracy Hollis

11:30 - 11:50 a.m. HSIN Outreach, Communications & 

Training

Melvin Brown II

11:50 – 1:00 p.m. Lunch

1:00 – 1:25 p.m. HSIN Program Management James Lanoue

1:30 – 2:15 p.m. HSIN Release 3’s Alignment to the 

National Strategy for Information Sharing 

and Safeguarding

Kshemendra Paul

2:15 – 2:30 p.m. HSIN and the Office of Operations 

Coordination

Richard Chavez

2:30 – 2:50 p.m. Acquisition Review Process & Portal 

Consolidation

Denzil Thies

2:50 – 3:10 p.m. HSIN Policy & Governance Michael Brody

3:10 – 3:25 p.m. Overall Program Status & Risk Mitigation Denzil Thies

3:25 – 3:40 p.m. Break

3:40 – 4:15 p.m. Open Discussion David Steigman

4:15 – 4:40 p.m. Advisory Committee Ethics Mike Waters (OGC)

4:45 – Open HSIN AC Member Discussions HSIN AC Chair/Vice Chair 

(Rolando Rivero, Ron Leavell)

5:00 p.m. Adjourn
DHS – HSIN Advisory Committee (AC) MEETING

1300 Pennsylvania Avenue NW Washington, D.C. 20004

February 27th- 28th

Open to the Public and Press

2

(Day TWO: February 28, 2013)

TIME SESSION SPEAKER

9:00 – 9:15 a.m. Welcome Donna Roy/David Steigman

9:15 – 9:30 a.m. HSIN Cooperation with Other Key DHS 

Programs

Dan Cotter

9:30 – 10:00 a.m. HSIN Cooperation with Other Key DHS 

Programs Part 2

Don Triner

10:00 a.m. Break

10:15 – 10:45 a.m. NIAC Recommendations/HSIN Impact Nancy Wong

10:45 – 11:05 a.m. HSIN Program: Where We Need Your 

Advice

James Lanoue

11:05 – 11:30 DHS Expense Reimbursement Leilani Cartledge

11:30 – 12:30 p.m. Lunch

12:30 – 1:00 p.m. HSIN AC Members Formulate 

Recommendations

HSIN AC Chair/Vice Chair (Rolando 

Rivero, Ron Leavell)

1:00 – 1:15 p.m. HSIN’s Progress and Challenges: 

Program Status Update

Richard Spires

1:15 – 2:00 p.m. HSIN AC Members Formulate 

Recommendations (cont.)

HSIN AC Chair/Vice Chair (Rolando 

Rivero, Ron Leavell)

2:00 p.m. Adjourn
IV 

115TH CONGRESS 

2D SESSION H. RES. 1153 

Honoring Jacob Anthony deGrom, starting pitcher for the New York Mets, 

for winning the 2018 National League Cy Young Award. 

IN THE HOUSE OF REPRESENTATIVES 

NOVEMBER 16, 2018 

Mr. KING of New York (for himself, Mr. SUOZZI, and Mr. ENGEL) submitted 

the following resolution; which was referred to the Committee on Oversight and Government Reform 

RESOLUTION 

Honoring Jacob Anthony deGrom, starting pitcher for the 

New York Mets, for winning the 2018 National League 

Cy Young Award. 

Whereas, during the 2018 Major League Baseball season, 

Jacob deGrom led the National League with a 1.70 

earned run average; 

Whereas, during the 2018 Major League Baseball season, 

Jacob deGrom finished second in strikeouts in the National League with 269 Ks; 

Whereas, during the 2018 Major League Baseball season, 

Jacob deGrom finished second in walks and hits per innings pitched (WHIP) in the National League with a .91 

WHIP; and 


pamtmann on DSKBFK8HB2PROD with BILLS
2 

•HRES 1153 IH 

Whereas the Baseball Writers’ Association of America saw fit 

to award Jacob deGrom with the National League Cy 

Young Award for his dominant 2018 season: Now, therefore, be it 

1 Resolved, That the House of Representatives— 

2 (1) honors Jacob Anthony deGrom for being 

3 awarded the National League Cy Young Award for 

4 the 2018 season; and 

5 (2) wishes Jacob deGrom continued success on 

6 and off the baseball diamond. 

Æ 


pamtmann on DSKBFK8HB2PROD with BILLS
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel; Review of Collaborative Minority Alcohol Research Development (U54).                    

*Date:*                         April 6, 2010.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.                    

*Contact Person:*                         Ranga Srinivas, PhD, Chief, Extramural Project Review Branch,  Office of Extramural Activities, National Institutes of Health, National Institute on Alcohol Abuse & Alcoholism, 5635 Fishers Lane, Room 2085, Rockville, MD 20852.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; 93101, ARRA Related Biomedical Research and Research Support Awards., National Institutes of Health, HHS)

Dated: February 23, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-4212 Filed 3-1-10; 8:45 am]

BILLING CODE 4140-01-M
Materials Not Included in

Airworthiness Directive (AD) Docket

 Docket Number: FAA-2014-0774

 Directorate Identifier: 2013NM154AD

747-53A2562, R2 --- 5/31/07

Name/Description of Item(s) Not Included in FDMS Docket and Maintained in the 

Supplemental AD Docket

MAY BE VIEWED AT: Federal Aviation Administration

Transport Airplane Directorate

Rules Docket

1601 Lind Ave. SW.,

Renton, WA 98057

425.227.1221

DURING THE HOURS OF: 9 a.m. and 3 p.m., Monday through Friday,

except Federal holidays.

Form Date: 03/05/2008
<PAGE>   1

                                                                    EXHIBIT 23.2

               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS



         We consent to the incorporation by reference in the Registration
Statement (Form S-8) pertaining to the registration of 100,000 additional shares
of common stock issuable under the 1996 Employee Stock Purchase Plan of SeaMED
Corporation of our report dated August 11, 1997 with respect to the financial
statements and schedule of SeaMED Corporation included in its Annual Report
(Form 10-K) for the year ended June 30, 1997.


         


Seattle, Washington                    ERNST & YOUNG, LLP
April 21, 1998
I 

118TH CONGRESS 

2D SESSION H. R. 7373 

To direct the Secretary of Health and Human Services, acting through 

the Director of the Centers for Disease Control and Prevention, to 

include alpha-gal syndrome on the list of nationally notifiable diseases. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 15, 2024 

Mr. GARBARINO (for himself, Ms. SPANBERGER, Mr. THOMPSON of Pennsylvania, and Ms. NORTON) introduced the following bill; which was referred 

to the Committee on Energy and Commerce 

A BILL 

To direct the Secretary of Health and Human Services, 

acting through the Director of the Centers for Disease 

Control and Prevention, to include alpha-gal syndrome 

on the list of nationally notifiable diseases. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Recognize AGS Act’’. 

5 SEC. 2. INCLUSION OF ALPHA-GAL SYNDROME ON LIST OF 

6 NATIONALLY NOTIFIABLE DISEASES. 

7 The Secretary of Health and Human Services, acting 

8 through the Director of the Centers for Disease Control 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7373 IH

1 and Prevention, shall take such steps as may be necessary 

2 to include alpha-gal syndrome on the list of nationally 

3 notifiable diseases published by the Centers for Disease 

4 Control and Prevention. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
EPA DR # 4025 A pril 27, 2010EPA DR # 4025 A pril 27, 2010
7 IR n F/,114

‘71:1 1."C

IN THE SUPREME COURT OF THE STATE OF MONTANA

DA 21-0056

JOHN RICHARDS, LINDA MILLER and

LARRY RICHARDS,

Petitioners and Appellants.

FILE

APR 0 6 2021

Bowen Gret-.:nyvo0O

Clerk of Supreme Court

State of Montana

v. ORDER

MONTANA DEPARTMENT OF NATURAL

RESOURCES AND CONSERVATION,

Respondent and Appellee.

Representing himself, Appellant John Richards moves for a stay pending his appeal

of the District Court's order dismissing his petition for judicial review of the final order by

the Department of Natural Resources and Conservation (DNRC) cancelling a lease.

Appellee DNRC has not filed a response. Richards also seeks an extension of time within

which to file his opening brief.

Richards appeals a January 5, 2021 Order of the Fourth Judicial District Court,

Missoula County, dismissing his petition for judicial review, without prejudice, because

Richards did not include the grounds for relief from the Final Agency Order, as required

by § 2-4-702(2)(a)(i)-(iv), and (b), MCA.' On February 23, 2021, the District Court denied

Richards's Motion for Stay of Execution Pending Appeal.

Under the Montana Rules of Appellate Procedure, a person first must seek a stay in

District Court. M. R. App. P. 22(1)(a)(i). Richards sought a stay in the District Court,

which denied his request. When reviewing a district court's denial of a motion for stay,

this Court is guided by Rule 22(2)(a), which requires that a party seeking relief from the

order file a motion within 11 days of the order and demonstrate good cause for the relief

I The District Court noted that only Petitioner Larry Richards had signed the Petition and that

Larry Richards therefore was the only Petitioner properly before the court. All three Petitioners

signed and filed notices of appeal, but John Richards alone filed the instant Motion to Stay.

04/06/2021

Case Number: DA 21-0056
requested. Richards's motion, dated March 8—the date due for filing—was not filed until

March 10, 2021, and is therefore untimely. We conclude further that Richards has not

demonstrated good cause for a stay. He states his desire for the lease to be transferred to

an acceptable purchaser so that his lease improvements are not forfeited, but he does not

explain why immediate relief is needed from the District Court's direction that he refile the

petition for judicial review in compliance with requirements of the Montana Administrative

Procedure Act. Although Richards requests mediation, the Rules governing appellate

mediation do not apply to this appeal because it concerns judicial review.

M. R. App. P. 7(2).

IT IS THEREFORE ORDERED that Richards's Motion for Stay is DENIED.

IT IS FURTHER ORDERED that Richards's Motion for Extension of Time is

GRANTED. The opening brief shall be filed on or before May 14, 2021.

The Clerk is directed to provide a copy of this Order to counsel of record and to

John Richards along with a copy of this Court's Civil Appellate Handbook.

DATED this 4. day of April, 2021.

-0-01, ,,(L)fr 

Chief Justice

Justices

2
UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

REGION 6

1445 ROSS AVENUE, SUITE 1200

DALLAS. TX 75202·2733

DFr 1 ? ?008

CERTIFI ED :\'IAI L -

RETlJRN I~ECEIPT REOl!ESTED

C1inlon liregg IIl\eSlmenls. L.P. (Alln: John Jennings)

2 lOu Crnsb\ (iP. LLC

) 5~() Olj"cr

Houston. T\ 77007

Re: EPA's Approval

rillal Soil Remt'dial AClion Report (dated OS/~l)!08)

!Vlany Di\l'rsilicd Intert>sts. Inc. Superfund Site: Houston. Harris County. Texas

Dear \ lr. .kllllill~:":

TIlt" purpo:"l' of Ihis lettcr is 10 prmide the to.S, El1\'ironmt'ntal Proh:ction Agency's

(F P:\ ) apprp, ;II (If IiiI' '"Final Soi I Rel1ll'dial :\ction Report" (dnted OX 29iOS ). This deliverable

'''IS suhmillt.:d by Clllllllll Gn:gg }Jl\l'stml.:nts, I..P, (eG)) pursuant to Ihl.' ":\grl'ed On.lcr on

C(1J)Sl'lll (,\(X') and ("o\C'nant :"01 to SUl' for Operable Unil ) (On-Site Soils and Ground

\\:Itl'l'l." l'n~>l'li\ l' ~"p:l'll1hl'r :?9, 200(1: "11' tl1l' :'vlany Di\'l'rsilil'd Inh.·!'l'sls. Inl". Superfund SilL'

kh,:;lIl'd ill II11uslOI1. ! bITis County. Tl'\as. Till.' 'J t'\as COlJ1missionlin Fl1\ironmental Quality

Ulfll·lIr~· "ith lhl"'P,\':- :lpprO\;l1 oflhi:- dlll'UIlll'1l1.

Pka"t' l,;t11 l~araL'1 ('asano\a or my :-tal'l'. at (2141 (6)-7J,7- 7, if yllli ha\ L' any lJul:stinn:- Ill'

('(lmnll'111:- l'lllll:I.'rnin~ 1hi" lelll'r.

u:: \11, ( IHi:- .\m:lIldt·:- (Yill'lln l\:. IIJ..in~ I.I.PI

\Ir. ,IJlll ..... ;ltL""J..i f JSI·\C II

"" I'hdlil 1 \\ill""!' Ift'\;t" ( ,'mllli:":,,illll on I Il\ il'nnlllCntal (.'lI:dilY I

RecycledIRecyclabie • Printed with Vegetable on Based Inks on 100% Recycled Paper 140% Postconsumer)